OpGen Inc (OPGN)

[mick]

OpGen (OPGN)INVESTMENT SUMMARY OpGen is a diagnostic company focused on revolutionising the identification and treatment
of bacterial infections.

Its system allows for the detection of five pathogens and 47
resistance genes and mutations, while predicting the resistance for
14 antibiotics in less
than three hours, a major improvement over the two to three days current methods require.


It recently announced a plan to merge with Curetis,
a Germany-based molecular diagnostics
company with a similar focus on infectious disease.

Closure of the merger, which is subject
to shareholder votes, is expected in Q120.

INDUSTRY OUTLOOK
It currently takes days to test a patient sample to find out if they have an infection, what they
are infected with and to which drugs that infection might be susceptible. This can lead to a
delay in treatment or the wrong treatment being prescribed.

According to the Centers for
Disease Control and Prevention, there are over two million cases
of drug-resistant bacterial
infections every year.
Y/E Dec Revenue EBITDA PBT EPS P/E P/CF
(US$m) (US$m) (US$m) (c) (x) (x)
2017 3.2 (15.3) (15.6) (19624.85) N/A N/A
2018 2.9 (13.2) (13.4) (3351.27) N/A N/A
2019e 3.5 (12.3) (12.6) (642.50) N/A N/A
2020e 5.3 (15.7) (15.8) (281.16) N/A N/A